Company news

Journey Medical Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

March 20, 2024

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

March 17, 2024

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

March 14, 2024

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

March 12, 2024

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

March 10, 2024

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

January 4, 2024

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

January 1, 2024

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

December 5, 2023

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

November 6, 2023

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

October 30, 2023

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 vs. Solodyn

October 23, 2023

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

October 19, 2023

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

September 5, 2023

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

August 7, 2023

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

August 1, 2023

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

July 18, 2023

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

July 12, 2023

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

July 10, 2023

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of...

July 2, 2023

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

June 12, 2023

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 21, 2023

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

May 18, 2023

Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call

May 10, 2023

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

May 3, 2023

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

March 28, 2023

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

March 21, 2023

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 on Microbial Flora in a Separate Phase 1 Clinical Trial

March 17, 2023

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

March 15, 2023

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

March 6, 2023

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

January 19, 2023

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosacea

January 11, 2023

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

January 9, 2023

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic Data for DFD-29Phase 3, registrational studies remain on track for first half of 2023 topline data readout

December 21, 2022

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

December 19, 2022

Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

December 4, 2022

Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

November 9, 2022

Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022

November 2, 2022

Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences

October 3, 2022

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosacea

August 31, 2022

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

August 29, 2022

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

August 8, 2022

Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022

August 2, 2022

Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA, AMZEEQ and ZILXI Patent Exclusivity

May 25, 2022

Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity

May 23, 2022

Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

May 22, 2022

Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

May 9, 2022

Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022

May 2, 2022

Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

April 3, 2022

Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

March 22, 2022

Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022

March 17, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks